Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the ...
New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...
AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...
Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...
The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio – which was acquired last year – and ...
Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...
ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...
As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback